Consensus Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
28 ^USD	-0.39%		-0.57%	-0.32%

04-09	Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	MT
03-05	Transcript : Royalty Pharma plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM

Evolution of the average Target Price on Royalty Pharma plc

Price target over the last 5 years

History of analyst recommendation changes

c1ea458b7.CNgtlnaX_MvF1xcrxp67DmYruAjLINrf3sul1N82lUk.UL9K8wzQkrvxjntGotnoTBJ730mzZa-TsJT_uZtGpxlesFnQN9WT-JzgYA~8790b207a30aed951b07580615bddf21

Analyst Recommendations on Royalty Pharma plc

Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	04-09	MT
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	02-20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	02-20	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	12-12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	12-12
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating	11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating	23-08-09	MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating	23-04-10	MT
Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	23-04-04	AQ
Bank of England lifts rates by 25 basis points	23-03-23	AN
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating	23-02-16	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating	22-12-06	MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	22-11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating	22-11-09	MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating	22-10-18	MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating	22-08-08	MT
Goldman Sachs Adjusts Price Target for Royalty Pharma to $56 From $55, Maintains Buy Rating	22-08-05	MT
Citigroup Adjusts Price Target on Royalty Pharma to $60 From $50, Reiterates Buy Rating	22-07-29	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $55 From $57, Maintains Buy Rating	22-07-28	MT
Tigress Financial Adjusts Royalty Pharma's Price Target to $57 From $52, Maintains Buy Rating	22-07-14	MT
UBS Raises Royalty Pharma's Price Target to $50 From $47, Buy Rating Maintained	22-07-12	MT